3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies - Related Studies

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

This study has been completed.

Study NCT00077181. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia

2	Additional conditions recognized in this trial
		Hematologic Neoplasms

3	More general conditions related to this trial
		Hematologic Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site

4	Interventions listed in this trial
		cytarabine
		triapine

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		University of Chicago
		National Cancer Institute (NCI)